- The country with an increasing use rate of immunoglobulin (Ig) currently imports about 85% of its Ig needs for patients Canada who rely on this life-saving plasma protein therapy
- Building on its investment in a large-scale fractionation plant in Montrealwill produce Grifols plasma, which will be sourced in Canada Supply final product exclusively for Canadian Blood Services to help achieve at least 50% Ig self-sufficiency for Canadians
- An additional 2.4 million grams of Ig will be provided annually to Canadian patients and Canadian Blood Services under a 15-year contract with options to extend, at pricing based on western market values and reviewed regularly
- Once again, Grifols demonstrates its global leadership in forging alliances between the plasma industry and the public sector as the best way to ensure plasma self-sufficiency
Barcelona, Spain, September 7, 2022 /PRNewswire/ — Grifols GRF GRF GRFSa global leader in plasma medicines that has helped improve people’s health and well-being for more than 110 years, announced today that it has signed a landmark long-term agreement with Canadian Blood Services. canada national blood agency to significantly increase the country’s self-sufficiency in immunoglobulin (Ig) drugs, essential plasma protein therapies to treat a wide range of immune deficiencies and other diseases.
It is the first-ever agreement of its kind and will ensure that Canadian plasma is processed on Canadian soil into Ig medicines for the exclusive needs of thousands of patients across the country who are critically dependent on these life-saving therapies.
Canada has a high Ig consumption rate and currently has to import up to 85% of its Ig, with demand growing at an average of 5-8% per year.
The collaboration agreement with Canadian Blood Services, part of Grifols’ long-term global growth strategy, will be combined with the work already done by Canadian Blood Services to accelerate this canada Ig degree of self-sufficiency of…
